Connect public, paid and private patent data with Google Patents Public Datasets

Surgically implanted devices having reduced scar tissue formation

Download PDF

Info

Publication number
US20040006296A1
US20040006296A1 US10351207 US35120703A US2004006296A1 US 20040006296 A1 US20040006296 A1 US 20040006296A1 US 10351207 US10351207 US 10351207 US 35120703 A US35120703 A US 35120703A US 2004006296 A1 US2004006296 A1 US 2004006296A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
anti
proliferative
drug
rapamycin
surgical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10351207
Inventor
Robert Fischell
David Fischell
Tim Fischell
Scott Fischell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afmedica Inc
Original Assignee
Afmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06166Sutures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/064Surgical staples, i.e. penetrating the tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831Material properties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0063Implantable repair or support meshes, e.g. hernia meshes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00451Plasters use for surgical sutures, e.g. butterfly type
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424Anti-adhesion agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • A61L2300/604Biodegradation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622Microcapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/626Liposomes, micelles, vesicles

Abstract

This invention is an anti-proliferative drug placed onto or within a sterile sheet or mesh that is designed to be placed between internal body tissues to prevent the formation of post-operative adhesions, which adhesions are really scar tissue formation. This mesh or gauze onto or into which the drug is placed may be either a permanent implant or it may be biodegradable. By impregnating an existing product such as the Johnson & Johnson SURGICEL™ absorbable hemostat gauze-like sheet with an anti-proliferative drug such as Rapamycin or Taxol, the biodegradable, drug impregnated mesh would act as a barrier to cell proliferation and hence be a deterrent to the formation of adhesions. Another embodiment of this invention is an anti-proliferative drug attached to a bandage that is placed onto a cut in the skin to decrease scar tissue formation. Still another embodiment of the invention is an anti-proliferative drug that is attached to a surgical suture or coated onto a surgical staple both of which are used for connecting human tissues. The suture or staple then being more capable for decreasing cellular proliferation where the suture or staple material passes through the human tissue.

Description

    REFERENCE TO A PREVIOUS PATENT APPLICATION
  • [0001]
    This is a continuation-in-part application of the patent application Ser. No. 09/705,999 filed on Nov. 6, 2000.
  • FIELD OF USE
  • [0002]
    This invention is in the field of materials used to prevent the formation of scar tissue subsequent to a surgical procedure or accidental skin cut of a human subject.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Post-operative adhesions are a major problem following abdominal and other surgical procedures. These adhesions are caused by the unwanted proliferation of scar tissue between internal tissues and structures of the human body generally after surgery. Several companies have developed sheets of biodegradable mesh that can be placed between these structures to reduce the tissue growth. None are entirely effective as some scar tissue typically grows through the mesh. U.S. Pat. No. 5,795,286 describes the use of a beta emitting radioisotope to reduce the proliferation of tissue through a biocompatible material placed into the human body. Although radioisotopes may be effective at preventing the cell proliferation associated with adhesions, the limited shelf life and safety issues associated with radioisotopes makes them less than ideal for this purpose.
  • [0004]
    Recent publications (Transcutaneous Cardiovascular Therapeutics 2000 Abstracts) report a greatly reduced cell proliferation within angioplasty injured arteries when vascular stents used for recannalization are coated with an anti-proliferative drug such as Rapamycin (Sirolmus) or Taxol. However, these drugs have never been used for reducing cellular proliferation of tissues separated by a surgical procedure.
  • SUMMARY OF THE INVENTION
  • [0005]
    A first embodiment of this invention is a device consisting of a drug impregnated into, coated onto or placed onto a material sheet or mesh designed to be placed between internal body tissues that have been surgically separated to prevent the formation of post-operative adhesions, which adhesions are really scar tissue formation. A drug that is impregnated into a gauze-like material or coated onto the material or joined to the material by adhesion and/or capillary action is defined herein as a drug “attached” to a mesh. This mesh or gauze onto which the drug is attached may be either a permanent implant or it may be biodegradable. The drug can be attached to an existing product such as the Johnson & Johnson SURGICEL™ absorbable hemostat gauze-like sheet. With an anti-proliferative drug such as Rapamycin or Taxol which have a known effect on proliferating cells, the biodegradable mesh would decrease cellular proliferation and hence be a deterrent to the formation of adhesions. It is also envisioned that an anti-proliferative drug attached to a bandage could be placed onto a cut in the skin for reducing scar tissue formation. This cut could be accidental or a result of a surgical incision. It is also envisioned that an anti-proliferative drug could be attached to surgical suture material that is used (for example) to join together two blood generally cylindrical cavitys, i.e., an anastomosis, with the attached drug causing a reduction in cellular proliferation in the vicinity where the sutures penetrate through the human tissue. It should be understood that the suture material could be either soluble or insoluble and could be used for any application for which sutures are used. Still another embodiment of the present invention is an anti-proliferative drug coated onto a surgical staple thus reducing scar tissue around that staple. Still another embodiment of this invention is to attach an anti-proliferative drug to a device such as a buckle that is used for the treatment of a detached retina. Since scar tissue formation is one of the main complications of a retinal attachment procedure, by attaching an anti-proliferative drug to the buckle that is placed around the eye, there can be some reduction in scar tissue formation. It is also envisioned to attach an anti-proliferative drug attached to the outside of a cylindrical tube that is placed within a generally cylindrical cavity of the human body to decrease scar tissue formation after a surgical procedure on that generally cylindrical cavity. Such a generally cylindrical cavity might be a nostril after an operation for a deviated septum, a fallopian tube, a billiary duct, a urethra, (for example after prostate surgery) a ureter, a bronchial tube, etc. For such an application, the tube with the attached anti-proliferative drug could be biodegradable, remain implanted or it could be removed after a few days or weeks.
  • [0006]
    Another device that would benefit from a coating of an anti-proliferative agent such as Rapamycin is a prosthetic implant that is placed into a woman's breast after reconstructive or augmentative surgery. Breast implants typically form significant scar tissue around their surface after implantation. Coating the surface of the breast implant with a slowly releasing anti-proliferative agent can significantly reduce this scar tissue formation.
  • [0007]
    Still another application of these concepts is for aterio-venous fistulas that are used for kidney dialysis patients. These devices (which are also called a-v shunts) are used to connect an artery in an arm to a large vein in the same arm. The plastic a-v shunt is then penetrated by comparatively large needles through which the patient's blood is cleansed typically every other day. A frequent cause of failure for these shunts is caused by proliferative cell growth at the anastamosis where the shunt is joined to a vein. By having sutures coated with an anti-proliferative agent and by coating the interior and/or exterior of the a-v shunt with an anti-proliferative agent it is expected that the time for maintaining adequate blood flow through the vein will be extended.
  • [0008]
    In addition to applying the anti-proliferative drug by means of a device to which the anti-proliferative drug is attached, it is also envisioned to apply the anti-proliferative drug systemically by any one or more of the well known means for introducing a drug into a human subject. For example, an anti-proliferative drug could be applied by oral ingestion, by a transdermal patch, by a cream or ointment applied to the skin, by inhalation or by a suppository. Any of these methods being a systemic application of an anti-proliferative drug. It should be understood that such a drug should be applied systemically starting at least one day prior to a surgical procedure but could be started as long as 5 days prior to a surgical procedure. Furthermore, the drug should be applied for a period of at least one day after the procedure and for some cases as long as 60 days. It should be understood that an anti-proliferative drug could be given systemically without using any of the devices described herein. Preferably, the anti-proliferative drug would be given systemically in addition to the application of an anti-proliferative drug attached to any one or more of the devices described herein. It should also be understood that an optimum result might be obtained with using one anti-proliferative drug attached to a device with a second and/or third drug being used for systemic administration. A typical dose for a patient, for example with Rapomycin, would be 1.5 mg/kg per day. The dose would of course depend on the anti-proliferative drug that was used.
  • [0009]
    Thus it is an object of this invention to have a sheet of material that can be placed between internal body tissues, the material having an anti-proliferative drug attached to reduce scar tissue formation between adjacent layers of the human tissue.
  • [0010]
    Another object of this invention is to have a biodegradable sheet of material or mesh suitable for placement between body tissues including an attached drug that prevents the cellular proliferation associated with post-surgical adhesions.
  • [0011]
    Still another object of the invention is to have a bandage to which an anti-proliferative drug is attached that is placed onto a cut in the skin to reduce scar tissue formation.
  • [0012]
    Still another object of the invention is to have a suture material or surgical staple to which an anti-proliferative drug is attached.
  • [0013]
    Still another object of the invention is to have an anti-proliferative drug attached to the exterior of a cylindrical tube that is placed into a generally cylindrical cavity of the human body after a surgical procedure on that generally cylindrical cavity.
  • [0014]
    Still another object of the invention is to have a device implanted in a human subject, the device having an anti-proliferative agent attached; the device being a breast implant, an a-v shunt or an equivalent device for implantation into the human subject.
  • [0015]
    Still another object of this invention is to have the anti-proliferative drug be Rapamycin or an equivalent drug.
  • [0016]
    Still another object of this invention is to have the anti-proliferative drug be Taxol or an equivalent drug.
  • [0017]
    Still another object of the invention is to employ a device placed into or onto the body of a human subject, which device has an attached anti-proliferative drug, plus using the same or a different anti-proliferative drug as a medication to be applied systemically to the human subject from some time prior to a surgical procedure to some time after that procedure.
  • [0018]
    These and other objects and advantages of this invention will become obvious to a person of ordinary skill in this art upon reading of the detailed description of this invention including the associated drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0019]
    [0019]FIG. 1 is a plan view of a sheet or mesh onto which an anti-proliferative drug has been attached.
  • [0020]
    [0020]FIG. 2 is an enlargement of the cross section of a single strand of the mesh where the drug is embedded within the strand.
  • [0021]
    [0021]FIG. 3 is an enlargement of the cross section of a single strand of the mesh where the drug is coated onto the strand.
  • [0022]
    [0022]FIG. 4 is an enlargement of two strands of the mesh that have been dipped into a solution of an anti-proliferative drug thereby attaching the drug to the strands by adhesion and capillary action.
  • [0023]
    [0023]FIG. 5 shows a cross section of the mesh to which an anti-proliferative drug has been attached, the mesh being placed between two layers of tissue of the human body.
  • [0024]
    [0024]FIG. 6 is a cross section of the skin onto which is taped a bandage to which an anti-proliferative drug has been attached.
  • [0025]
    [0025]FIG. 7 is a cross section of a human breast into which a breast implant has been placed.
  • DETAILED DESCRIPTION OF THE DRAWINGS
  • [0026]
    [0026]FIG. 1 shows an absorbable hemostat mesh sheet 10 with mesh strands 12 and open spaces 11. The sheet 10 is designed to be placed post-operatively between internal body tissues that have been separated by a surgical procedure. The mesh strands 12 can be made from oxidized regenerated cellulose or other biodegradable materials with the anti-proliferative drug either embedded within the strands, coated onto the outer surfaces of the strands or held onto the strands by adhesion or capillary action. Any of these possibilities will be described herein as the drug being attached to the mesh or attached to the strand of the mesh.
  • [0027]
    [0027]FIG. 2 is an enlargement of a cross section of a single strand 12 of the mesh 10 in which the anti-proliferative drug 14 is embedded within the strand 12.
  • [0028]
    [0028]FIG. 3 is an enlargement of the cross section of a single strand 12 of the mesh where the anti-proliferative drug 17 is coated onto the exterior surface of the strand.
  • [0029]
    [0029]FIG. 4 is an enlargement of two adjacent strands 12 of the mesh 10 onto which an anti-proliferative drug 18 is attached by means of adhesion and capillary action.
  • [0030]
    [0030]FIG. 5 shows the anti-proliferative drug attached to the mesh 10 placed between two adjacent tissues 20 and 21 of a human body. The mesh 10 would be inserted during a surgical procedure typically just before closing of the surgical incision. When the biodegradable mesh 10 dissolves or is absorbed into the tissues 20 and 21, the anti-proliferative drug attached to the mesh 10 will become dispersed into the tissues 20 and 21. On the other hand, if the biocompatible sheet of material is not biodegradable, the anti-proliferative drug will remain at the site where it is placed for a longer period of time than if the material sheet is biodegradable. Similarly, the drug itself may be produced in a soluble or insoluble form. An insoluble form would remain at the treatment site longer than a soluble form.
  • [0031]
    The anti-proliferative drugs that may be used include cancer drugs such as Taxol and other known anti-proliferative drugs such as Rapamycin. Other drugs that could be used are Alkeran, Cytoxan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, taclolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
  • [0032]
    Although a mesh has been discussed herein, more generally, an anti-proliferative drug can be made to be part of any sheet of material that is or is not biodegradable, as long as the sheet of material is biocompatible. In any case the effect of the anti-proliferative drug that is attached to at least part of the sheet of material will decrease cellular proliferation and therefore decrease the formation of scar tissue and adhesions.
  • [0033]
    It should also be understood that the mesh 10 could be rolled into a cylinder and placed into a generally cylindrical cavity of the human body that has undergone a surgical procedure. The mesh 10, in a cylindrical form, could also be placed around an elastomer tube prior to placement in the human generally cylindrical cavity.
  • [0034]
    [0034]FIG. 6 is a cross section of a cut 23 in the skin 22 that is situated above the subcutaneous tissue 24. A bandage 25 to which an anti-proliferative drug has been attached is shown attached to the skin 22 by means of an adhesive tape 26. The purpose of the anti-proliferative drug is to reduce scar tissue formation in order to have an improved appearance of the skin. The bandage may also include an antiseptic agent to decrease the possibility of infection.
  • [0035]
    It should also be understood that an ointment that includes an anti-proliferative agent could be used separately from the bandage 25 of FIG. 6. The anti-proliferative agent would be selected from the group that includes Alkeran, Cytoxan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hoxalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, taclolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.
  • [0036]
    Another alternative embodiment of the invention is a suture material to which an anti-proliferative drug is attached. A drawing of a highly enlarged cross section of such a suture would be shown by FIG. 2 or 3. That is, FIG. 2 could be considered to be a cross section of a suture 12 into which is embedded an anti-proliferative drug 14. FIG. 3 could be considered a highly enlarged cross section of a suture 12 that is coated with an anti-proliferative drug 17. The object of attaching an anti-proliferative drug to a suture would be to reduce scar tissue formation where the suture penetrates through human tissue. This would be particularly true for the use a suture to join together two generally cylindrical cavitys, i. e., an anastamosis. This could be used for both soluble and insoluble suture materials. Furthermore, an anti-proliferative drug could be attached to any surgical staple that is used to join together human tissue after a surgical procedure. It should be understood that sutures or staples with an anti-proliferative agent attached could be used for joining any tissue of a human subject where it is desired to reduce cellular proliferation, i.e., the formation of adhesions or scar tissue.
  • [0037]
    [0037]FIG. 7 illustrates the implant into the breast of a human subject of a breast implant 31. Attached to the breast implant 31 would be an, anti-proliferative agent selected from the group that includes Rapamycin, Taxol, Alkeran, Cytoxan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, taclolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline. When a breast implant has an attached anti-proliferative agent, the scar tissue that typically forms around such an implant will be significantly reduced.
  • [0038]
    If an arterio-venus fistula shunt is placed into the arm of a dialysis patient, then the same type of anti-proliferative agent(s) as described above could be attached to that implanted device to increase the time during which the associated vein in the arm would remain patent.
  • [0039]
    Another application of the present invention is for prevention of scar tissue formation subsequent to a procedure for attaching a detached retina. This procedure uses what is called a “buckle” placed around the eye to cause re-attachment of the retina The extent of scar tissue formation after this procedure is performed can be decreased r by attaching an anti-proliferative drug to the buckle., The anti-proliferative drug would then find its way into the eye to decrease scar tissue formation.
  • [0040]
    For any of the applications described herein, the systemic application of one or more of the anti-proliferative agents that have been described could be used conjunctively to further minimize the creation of scar tissue.
  • [0041]
    Although only the use of certain anti-proliferative agents has been discussed herein, it should be understood that other medications could be added to the anti-proliferative drugs to provide an improved outcome for the patients. Specifically, for applications on the skin, an antiseptic, and/or anti-biotic, and/or analgesic agent could be added to an anti-proliferative ointment to prevent infection and/or to decrease pain. These other agents could also be applied for any other use of the anti-proliferative drugs that are described herein. It is further understood that any human subject in whom an anti-proliferative agent is used plus at least one of the other drugs listed above could also benefit from the systemic administration of one or more anti-proliferative agent that has been listed herein.
  • [0042]
    Various other modifications, adaptations, and alternative designs are of course possible in light of the above teachings. Therefore, it should be understood at this time that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described herein.

Claims (31)

We claim:
1. A composition, comprising a compound attached to surgical material, said compound selected from the group consisting of sirolimus and analogs of sirolimus.
2. The composition of claim 1, wherein said surgical material comprises a biodegradable sheet of material.
3. The composition of claim 1, wherein said surgical material comprises mesh.
4. The composition of claim 1, wherein said surgical material comprises an implantable device.
5. The composition of claim 1, wherein said analogs of sirolimus comprise: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin.
6. A composition, comprising a compound attached to a bandage, said compound selected from the group consisting of sirolimus and analogs of sirolimus.
7. The composition of claim 5, wherein said analogs of sirolimus comprise: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin.
8. A composition, comprising a compound attached to a surgical suture, said compound selected from the group consisting of sirolimus and analogs of sirolimus.
9. The composition of claim 7, wherein said analogs of sirolimus comprise: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin.
10. A method, comprising:
a) providing;
i) a subject on whom a surgical procedure is performed;
ii) a compound selected from the group consisting of sirolimus and analogs of sirolimus;
iii) a surgical material, to which said compound is attached;
b) introducing said surgical material into said subject under conditions such that the surgical outcome is improved.
11. The method of claim 10, wherein said surgical material further comprises at least one second compound selected from the group consisting of antiseptic agents, antibiotic agents and analgesic agents.
12. The method of claim 10, wherein said analogs of sirolimus are selected from the group consisting of SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin.
13. The method of claim 10, wherein said surgical material comprises a biodegradable sheet of material.
14. The method of claim 10, wherein said surgical material comprises a mesh.
15. The method of claim 10, wherein said surgical material comprises a suture.
16. The method of claim 10, wherein said surgical material comprises an implantable device.
17. The method of claim 10, wherein said second compound is released systemically.
18. The method of claim 10, wherein said compound is administered at least one day prior to said surgical procedure.
19. The method of claim 10, wherein said compound is administered at least one day following said surgical procedure.
20. The method of claim 17, wherein said second compound is administered by a route selected from the group consisting of oral, transdermal, topical, inhalation and by suppository.
21. A method, comprising:
a) providing;
i) a subject on whom a surgical procedure has been performed;
ii) a compound selected from the group consisting of sirolimus and analogs of sirolimus;
iii) a surgical material, to which said compound is attached;
b) introducing said surgical material into said subject under conditions such that scarring is reduced.
22. The method of claim 21, wherein said surgical material further comprises at least one second compound selected from the group consisting of antiseptic agents, antibiotic agents and analgesic agents.
23. The method of claim 21, wherein said analogs of sirolimus are selected from the group consisting of SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin.
24. The method of claim 21, wherein said surgical material comprises a biodegradable sheet of material.
25. The method of claim 21, wherein said surgical material comprises a mesh.
26. The method of claim 21, wherein said surgical material comprises a suture.
27. The method of claim 21, wherein said surgical material comprises an implantable device.
28. The method of claim 22, wherein said second compound is administered systemically.
29. The method of claim 21, wherein,said compound is administered at least one day prior to said surgical procedure.
30. The method of claim 21, wherein said compound is administered at least one day following said surgical procedure.
31. The method of claim 28, wherein said second compound is administered by a route selected from the group consisting of oral, transdermal, topical, inhalation and by suppository.
US10351207 2000-11-06 2003-01-24 Surgically implanted devices having reduced scar tissue formation Abandoned US20040006296A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US70599900 true 2000-11-06 2000-11-06
US09772693 US6534693B2 (en) 2000-11-06 2001-01-31 Surgically implanted devices having reduced scar tissue formation
US10351207 US20040006296A1 (en) 2000-11-06 2003-01-24 Surgically implanted devices having reduced scar tissue formation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10351207 US20040006296A1 (en) 2000-11-06 2003-01-24 Surgically implanted devices having reduced scar tissue formation
US10431701 US20040018228A1 (en) 2000-11-06 2003-05-07 Compositions and methods for reducing scar tissue formation
US11084948 US20050281860A1 (en) 2000-11-06 2005-03-21 Surgically implanted devices having reduced scar tissue formation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09772693 Continuation US6534693B2 (en) 2000-11-06 2001-01-31 Surgically implanted devices having reduced scar tissue formation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10431701 Continuation-In-Part US20040018228A1 (en) 2000-11-06 2003-05-07 Compositions and methods for reducing scar tissue formation

Publications (1)

Publication Number Publication Date
US20040006296A1 true true US20040006296A1 (en) 2004-01-08

Family

ID=24835796

Family Applications (3)

Application Number Title Priority Date Filing Date
US09772693 Active US6534693B2 (en) 2000-11-06 2001-01-31 Surgically implanted devices having reduced scar tissue formation
US10351207 Abandoned US20040006296A1 (en) 2000-11-06 2003-01-24 Surgically implanted devices having reduced scar tissue formation
US11084948 Abandoned US20050281860A1 (en) 2000-11-06 2005-03-21 Surgically implanted devices having reduced scar tissue formation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09772693 Active US6534693B2 (en) 2000-11-06 2001-01-31 Surgically implanted devices having reduced scar tissue formation

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11084948 Abandoned US20050281860A1 (en) 2000-11-06 2005-03-21 Surgically implanted devices having reduced scar tissue formation

Country Status (5)

Country Link
US (3) US6534693B2 (en)
JP (1) JP2004529667A (en)
CA (1) CA2428082A1 (en)
EP (1) EP1385458A4 (en)
WO (1) WO2002036054A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146546A1 (en) * 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
US20050149158A1 (en) * 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and anti-scarring agents
US20060067976A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
US20060112536A1 (en) * 2003-09-15 2006-06-01 Atrium Medical Corporation Method of coating a folded medical device
US20070071798A1 (en) * 2004-09-28 2007-03-29 Atrium Medical Corporation Perforated bioabsorbable oil film and methods for making the same
US20070202149A1 (en) * 2005-10-15 2007-08-30 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US20080109017A1 (en) * 2006-11-06 2008-05-08 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080113001A1 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20080206305A1 (en) * 2004-09-28 2008-08-28 Atrium Medical Corporation Implantable barrier device
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US20090047414A1 (en) * 2004-09-28 2009-02-19 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20090181937A1 (en) * 2004-09-28 2009-07-16 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090208552A1 (en) * 2004-09-28 2009-08-20 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20100233232A1 (en) * 2009-03-10 2010-09-16 Swanick Thomas M Fatty-acid based particles
US20110118703A1 (en) * 1999-01-25 2011-05-19 Herweck Steve A Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US20110210121A1 (en) * 2007-02-13 2011-09-01 Gateway Plastics, Inc. Container system
US20110237542A1 (en) * 2008-12-01 2011-09-29 Shin Poong Pharmaceutical Co., Ltd. Composition for preventing adhesion
US8263102B2 (en) 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US8776716B2 (en) 2011-08-09 2014-07-15 Biomet Biologics, Llc Surgical mesh spray and delivery system
US9220807B2 (en) * 2012-11-04 2015-12-29 Miba Medical Inc. Non-toxic cross-linker for hyaluronic acid
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7963997B2 (en) 2002-07-19 2011-06-21 Kensey Nash Corporation Device for regeneration of articular cartilage and other tissue
US8795242B2 (en) * 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
KR20000015944A (en) * 1996-05-24 2000-03-15 팜 윌리암 엔. Compositions and methods for treating or preventing diseases of body passageways
US7231254B2 (en) * 1998-08-05 2007-06-12 Bioneuronics Corporation Closed-loop feedback-driven neuromodulation
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US7974696B1 (en) 1998-08-05 2011-07-05 Dilorenzo Biomedical, Llc Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
US7403820B2 (en) * 1998-08-05 2008-07-22 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US7277758B2 (en) * 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US8762065B2 (en) * 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US7747325B2 (en) * 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US7853329B2 (en) * 1998-08-05 2010-12-14 Neurovista Corporation Monitoring efficacy of neural modulation therapy
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US7209787B2 (en) * 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US6923927B2 (en) 2000-10-03 2005-08-02 Atrium Medical Corporation Method for forming expandable polymers having drugs or agents included therewith
US6616876B1 (en) 2000-10-03 2003-09-09 Atrium Medical Corporation Method for treating expandable polymer materials
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
RU2345719C2 (en) * 2001-01-16 2009-02-10 Васкулар Терапиез, Ллс. Method of prevention or treatment of reduction of access for vessel hemodialysis and device for its realisation and other vascular grafts
US6629988B2 (en) * 2001-08-28 2003-10-07 Ethicon, Inc. Composite staple for completing an anastomosis
WO2003061519A3 (en) * 2002-01-18 2004-08-26 Massachusetts Eye & Ear Infirm Methods and compositions for preserving the viability of photoreceptor cells
US20040087613A1 (en) * 2002-01-29 2004-05-06 Molmenti Ernesto P. Prevention of adhesions with rapamycin
EP1482975B1 (en) * 2002-01-29 2006-12-13 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Prevention of tissue adhesion
EP1516597A4 (en) * 2002-06-27 2010-11-10 Microport Medical Shanghai Co Drug eluting stent
DK1589031T3 (en) * 2002-07-16 2007-12-10 Biotica Tech Ltd Fremstillingaf polyketides and other natural products
US7101381B2 (en) * 2002-08-02 2006-09-05 C.R. Bard, Inc. Implantable prosthesis
ES2494791T3 (en) 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Use of rapamycin for the treatment or prevention of macular degeneration
CA2500067A1 (en) * 2002-09-26 2004-04-08 Endovascular Devices, Inc. Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
WO2004060283A3 (en) 2002-12-16 2005-03-24 David S Garvey Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
WO2004060405A3 (en) * 2002-12-30 2005-10-20 Angiotech Int Ag Tissue reactive compounds and compositions and uses thereof
DE10305811A1 (en) * 2003-02-12 2004-08-26 Ethicon Gmbh Surgical implant, preferably in net form, comprises basic structure containing anabolic steroid and corticosteroid to accelerate healing and reduce scar contraction
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
EP1682132A1 (en) * 2003-09-18 2006-07-26 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005051232A3 (en) * 2003-11-20 2005-12-08 Angiotech Int Ag Soft tissue implants and anti-scarring agents
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
US8277831B2 (en) 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7758654B2 (en) 2004-05-20 2010-07-20 Kensey Nash Corporation Anti-adhesion device
KR100596218B1 (en) * 2004-06-10 2006-07-03 (주)액세스 플러스 Tube conntecting artery to vein for hemodialysis
US7922702B2 (en) * 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
WO2006036970A3 (en) * 2004-09-28 2006-08-17 Atrium Medical Corp Method of thickening a coating using a drug
EP3025713A1 (en) 2005-02-09 2016-06-01 Santen Pharmaceutical Co., Ltd Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2357093T3 (en) * 2005-05-18 2011-04-18 Gt Urological, Llc For drug eluting implantable devices for incontinence.
WO2007011880A3 (en) 2005-07-18 2007-06-21 Minu Llc Enhanced ocular neuroprotection/neurostimulation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
WO2007019427A3 (en) * 2005-08-08 2007-05-03 Cynthia Lee Grosskreutz Methods and compositions for preserving the viability of photoreceptor cells
US8067189B2 (en) * 2005-09-01 2011-11-29 Bristol-Myers Squibb Company Methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators by measuring the level of collagen type IV
US8725243B2 (en) * 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US8868172B2 (en) * 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
US20070149952A1 (en) * 2005-12-28 2007-06-28 Mike Bland Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser
EP1978930A2 (en) * 2006-01-31 2008-10-15 Angiotech Pharmaceuticals, Inc. Sutures and anti-scarring agents
WO2007092620A3 (en) 2006-02-09 2009-03-26 Macusight Inc Stable formulations, and methods of their preparation and use
US20070287931A1 (en) * 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
CA2648066C (en) 2006-03-31 2012-07-03 Forsight Labs, Llc Drug delivery methods, structures, and compositions for nasolacrimal system
WO2007150003A3 (en) * 2006-06-23 2008-11-06 Neurovista Corp Minimally invasive monitoring systems and methods
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US8883190B2 (en) 2006-12-01 2014-11-11 Wake Forest University Health Sciences Urologic devices incorporating collagen inhibitors
WO2008092133A3 (en) 2007-01-25 2008-09-12 Neurovista Corp Methods and systems for measuring a subject's susceptibility to a seizure
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US7823761B2 (en) * 2007-05-16 2010-11-02 The Invention Science Fund I, Llc Maneuverable surgical stapler
US7798385B2 (en) * 2007-05-16 2010-09-21 The Invention Science Fund I, Llc Surgical stapling instrument with chemical sealant
US7832611B2 (en) * 2007-05-16 2010-11-16 The Invention Science Fund I, Llc Steerable surgical stapler
US8485411B2 (en) 2007-05-16 2013-07-16 The Invention Science Fund I, Llc Gentle touch surgical stapler
US7922064B2 (en) 2007-05-16 2011-04-12 The Invention Science Fund, I, LLC Surgical fastening device with cutter
US20080287987A1 (en) * 2007-05-16 2008-11-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Dispensing system for tissue sealants
US7810691B2 (en) * 2007-05-16 2010-10-12 The Invention Science Fund I, Llc Gentle touch surgical stapler
US8721711B2 (en) * 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
RU2482822C2 (en) * 2007-09-07 2013-05-27 Клт Инк. Instruments for inserting and removal of lacrimal implants
DK2207529T3 (en) * 2007-09-07 2015-03-09 Mati Therapeutics Inc PHARMACEUTICAL cores for the sustained release of therapeutic agents
US20090112243A1 (en) * 2007-10-25 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Surgical cutter with dispensing system for tissue sealants
US20090112256A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Suturing device with tissue sealant dispenser
US20090143816A1 (en) * 2007-11-30 2009-06-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Grasper with surgical sealant dispenser
WO2009079388A3 (en) * 2007-12-14 2009-09-03 Oregon Health & Science University Drug delivery cuff
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US20090248070A1 (en) * 2008-04-01 2009-10-01 Kosa Timothy D Anchoring Suture
US9132088B2 (en) * 2008-04-30 2015-09-15 Mati Therapeutics Inc. Composite lacrimal insert and related methods
JP2011520805A (en) * 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー,インク.Qlt Plug Delivery,Inc. Sustained delivery of the active agent for glaucoma and ocular hypertension treatment
CA2728623A1 (en) * 2008-06-24 2010-01-21 Qlt Plug Delivery, Inc. Combination treatment of glaucoma
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
JP5885244B2 (en) * 2009-01-23 2016-03-15 マティ セラピューティクス,インク. Sustained release delivery of one or more agents
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
DE102009030931A1 (en) 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Surgical wound sealing element for sealing wound in surgical joint in e.g. intestine of human, has body coated with anti-inflammatory composition and designed as thread that comprises fibers, which are interlaced together
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
JP2013520239A (en) * 2010-02-22 2013-06-06 マッツォッキ,ルディ,エイ Minimally invasive methods and apparatus for reconstructing the retina
US20110219325A1 (en) * 2010-03-02 2011-09-08 Himes David M Displaying and Manipulating Brain Function Data Including Enhanced Data Scrolling Functionality
JP2015513961A (en) * 2012-03-28 2015-05-18 エシコン・エンド−サージェリィ・インコーポレイテッドEthicon Endo−Surgery,Inc. Tissue thickness compensator and a method of manufacturing the same
US20140288582A1 (en) * 2011-06-21 2014-09-25 Bvw Holding Ag Implant Localization Device
EP3120834A1 (en) 2011-08-29 2017-01-25 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
US20130202656A1 (en) 2012-02-03 2013-08-08 Dynasil Biomedical Corporation Systems and kits for the fabrication of tissue patches
US9440009B2 (en) * 2012-02-16 2016-09-13 DePuy Synthes Products, Inc. Drug eluting insert for implantable body
EP2844224A4 (en) 2012-05-03 2016-02-24 Mati Therapeutics Inc Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US9833538B2 (en) 2015-08-07 2017-12-05 Xcede Technologies, Inc. Adhesive compositions and related methods
US9540548B1 (en) 2015-08-07 2017-01-10 Xcede Technologies, Inc. Adhesive compositions and related methods

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176664A (en) * 1978-03-13 1979-12-04 Stanley Kalish Impregnated bandage
US4747845A (en) * 1983-10-17 1988-05-31 Enquay Pharmaceutical Associates Synthetic resin matrix system for the extended delivery of drugs
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4865031A (en) * 1985-07-12 1989-09-12 Keeffe Paul J O Fabric and method of use for treatment of scars
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US4952403A (en) * 1987-06-19 1990-08-28 President And Fellows Of Harvard College Implants for the promotion of healing of meniscal tissue
USRE33375E (en) * 1984-05-29 1990-10-09 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US5134229A (en) * 1990-01-12 1992-07-28 Johnson & Johnson Medical, Inc. Process for preparing a neutralized oxidized cellulose product and its method of use
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5387589A (en) * 1991-07-25 1995-02-07 University Of Louisville Research Foundation, Inc. Method of treating ocular inflammation
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5618553A (en) * 1994-10-26 1997-04-08 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5677295A (en) * 1994-12-07 1997-10-14 American Home Prod Rapamycin 42-oximes and hydroxylamines
US5693607A (en) * 1992-10-29 1997-12-02 Segarini; Patricia R. Uses of TGF-β receptor fragment as a therapeutic agent
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
US5756673A (en) * 1994-12-06 1998-05-26 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US5767135A (en) * 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
US5795286A (en) * 1996-08-15 1998-08-18 Cathco, Inc. Radioisotope impregnated sheet of biocompatible material for preventing scar tissue formation
US5798334A (en) * 1995-09-28 1998-08-25 Colla-Gene, Inc. Pharmaceutical compositions for scarless tissue repair and regeneration and methods related thereto
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
US6063369A (en) * 1998-03-16 2000-05-16 Alterna, Inc. Quaternized hemp seed oil
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6124273A (en) * 1995-06-09 2000-09-26 Chitogenics, Inc. Chitin hydrogels, methods of their production and use
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6200985B1 (en) * 1995-06-09 2001-03-13 Novartis Ag Rapamycin derivatives
US6214873B1 (en) * 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
US6221099B1 (en) * 1992-05-20 2001-04-24 Boston Scientific Corporation Tubular medical prosthesis
US6231590B1 (en) * 1998-11-10 2001-05-15 Scimed Life Systems, Inc. Bioactive coating for vaso-occlusive devices
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6273908B1 (en) * 1997-10-24 2001-08-14 Robert Ndondo-Lay Stents
US6312713B1 (en) * 1998-06-12 2001-11-06 Bernard Korol Polymer matrices for storage and sustained release of drugs and chemicals
US20030216699A1 (en) * 2000-05-12 2003-11-20 Robert Falotico Coated medical devices for the prevention and treatment of vascular disease
US6702828B2 (en) * 1999-09-01 2004-03-09 Converge Medical, Inc. Anastomosis system
US6726923B2 (en) * 2001-01-16 2004-04-27 Vascular Therapies, Llc Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
US6730313B2 (en) * 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250516A (en) * 1986-04-17 1993-10-05 Uab Research Foundation Bioelastomeric materials suitable for the protection of burn areas or the protection of wound repair sites from the occurrence of adhesions
EP1512398A1 (en) * 1997-03-31 2005-03-09 Boston Scientific Limited Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6063396A (en) 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
US6015432A (en) * 1998-02-25 2000-01-18 Cordis Corporation Wire reinforced vascular prosthesis
EP1069874B1 (en) * 1998-04-07 2005-01-12 Macropore, Inc. Membrane with tissue-guiding surface corrugations
US8029561B1 (en) 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176664A (en) * 1978-03-13 1979-12-04 Stanley Kalish Impregnated bandage
US4747845A (en) * 1983-10-17 1988-05-31 Enquay Pharmaceutical Associates Synthetic resin matrix system for the extended delivery of drugs
USRE33375E (en) * 1984-05-29 1990-10-09 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4865031A (en) * 1985-07-12 1989-09-12 Keeffe Paul J O Fabric and method of use for treatment of scars
US4895566A (en) * 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4952403A (en) * 1987-06-19 1990-08-28 President And Fellows Of Harvard College Implants for the promotion of healing of meniscal tissue
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5134229A (en) * 1990-01-12 1992-07-28 Johnson & Johnson Medical, Inc. Process for preparing a neutralized oxidized cellulose product and its method of use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US5387589A (en) * 1991-07-25 1995-02-07 University Of Louisville Research Foundation, Inc. Method of treating ocular inflammation
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US6221099B1 (en) * 1992-05-20 2001-04-24 Boston Scientific Corporation Tubular medical prosthesis
US5693607A (en) * 1992-10-29 1997-12-02 Segarini; Patricia R. Uses of TGF-β receptor fragment as a therapeutic agent
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US5624893A (en) * 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
US5618553A (en) * 1994-10-26 1997-04-08 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5756673A (en) * 1994-12-06 1998-05-26 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US5677295A (en) * 1994-12-07 1997-10-14 American Home Prod Rapamycin 42-oximes and hydroxylamines
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6200985B1 (en) * 1995-06-09 2001-03-13 Novartis Ag Rapamycin derivatives
US6124273A (en) * 1995-06-09 2000-09-26 Chitogenics, Inc. Chitin hydrogels, methods of their production and use
US5798334A (en) * 1995-09-28 1998-08-25 Colla-Gene, Inc. Pharmaceutical compositions for scarless tissue repair and regeneration and methods related thereto
US5767135A (en) * 1995-12-29 1998-06-16 Fernandez-Pol; Jose Alberto Antiviral agent
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5795286A (en) * 1996-08-15 1998-08-18 Cathco, Inc. Radioisotope impregnated sheet of biocompatible material for preventing scar tissue formation
US6214873B1 (en) * 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6273908B1 (en) * 1997-10-24 2001-08-14 Robert Ndondo-Lay Stents
US6063369A (en) * 1998-03-16 2000-05-16 Alterna, Inc. Quaternized hemp seed oil
US6312713B1 (en) * 1998-06-12 2001-11-06 Bernard Korol Polymer matrices for storage and sustained release of drugs and chemicals
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
US6231590B1 (en) * 1998-11-10 2001-05-15 Scimed Life Systems, Inc. Bioactive coating for vaso-occlusive devices
US6702828B2 (en) * 1999-09-01 2004-03-09 Converge Medical, Inc. Anastomosis system
US6730313B2 (en) * 2000-01-25 2004-05-04 Edwards Lifesciences Corporation Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20030216699A1 (en) * 2000-05-12 2003-11-20 Robert Falotico Coated medical devices for the prevention and treatment of vascular disease
US6726923B2 (en) * 2001-01-16 2004-04-27 Vascular Therapies, Llc Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110118703A1 (en) * 1999-01-25 2011-05-19 Herweck Steve A Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US9050442B2 (en) 1999-01-25 2015-06-09 Atrium Medical Corporation Expandable fluoropolymer device for delivery of therapeutic agents and method of making
US20080085855A1 (en) * 2002-09-26 2008-04-10 Angiotech International Ag Perivascular wraps
US20040146546A1 (en) * 2002-09-26 2004-07-29 Angiotech Pharmaceuticals, Inc. Perivascular wraps
US20060112536A1 (en) * 2003-09-15 2006-06-01 Atrium Medical Corporation Method of coating a folded medical device
US8021331B2 (en) 2003-09-15 2011-09-20 Atrium Medical Corporation Method of coating a folded medical device
US20110213302A1 (en) * 2003-09-15 2011-09-01 Herweck Steve A Method of coating a folded medical device
US8308684B2 (en) 2003-09-15 2012-11-13 Atrium Medical Corporation Method of coating a folded medical device
US20050149158A1 (en) * 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and anti-scarring agents
US20050149080A1 (en) * 2003-11-10 2005-07-07 Angiotech International Ag Medical implants and anti-scarring agents
US8722077B2 (en) 2004-09-28 2014-05-13 Atrium Medical Corporation Drug delivery coating for use with a stent
US9827352B2 (en) 2004-09-28 2017-11-28 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9801913B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Barrier layer
US9682175B2 (en) 2004-09-28 2017-06-20 Atrium Medical Corporation Coating material and medical device system including same
US20080206305A1 (en) * 2004-09-28 2008-08-28 Atrium Medical Corporation Implantable barrier device
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US20090047414A1 (en) * 2004-09-28 2009-02-19 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20090181937A1 (en) * 2004-09-28 2009-07-16 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090208552A1 (en) * 2004-09-28 2009-08-20 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20070071798A1 (en) * 2004-09-28 2007-03-29 Atrium Medical Corporation Perforated bioabsorbable oil film and methods for making the same
US20060110457A1 (en) * 2004-09-28 2006-05-25 Atrium Medical Corporation Heat cured gel and method of making
US20060067983A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Stand-alone film and methods for making the same
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060067975A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation UV cured gel and method of making
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8962023B2 (en) 2004-09-28 2015-02-24 Atrium Medical Corporation UV cured gel and method of making
US8263102B2 (en) 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US20060067976A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US8858978B2 (en) 2004-09-28 2014-10-14 Atrium Medical Corporation Heat cured gel and method of making
US8795703B2 (en) 2004-09-28 2014-08-05 Atrium Medical Corporation Stand-alone film and methods for making the same
US8574618B2 (en) 2004-09-28 2013-11-05 Atrium Medical Corporation Perforated bioabsorbable oil film and methods for making the same
US20060078586A1 (en) * 2004-09-28 2006-04-13 Atrium Medical Corporation Barrier layer
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US20070202149A1 (en) * 2005-10-15 2007-08-30 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US9220820B2 (en) 2005-10-15 2015-12-29 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8501229B2 (en) 2005-10-15 2013-08-06 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US8124127B2 (en) 2005-10-15 2012-02-28 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US20080109017A1 (en) * 2006-11-06 2008-05-08 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080113001A1 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20080118550A1 (en) * 2006-11-06 2008-05-22 Atrium Medical Corporation Coated surgical mesh
US8574627B2 (en) 2006-11-06 2013-11-05 Atrium Medical Corporation Coated surgical mesh
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20110210121A1 (en) * 2007-02-13 2011-09-01 Gateway Plastics, Inc. Container system
US20110237542A1 (en) * 2008-12-01 2011-09-29 Shin Poong Pharmaceutical Co., Ltd. Composition for preventing adhesion
US8703740B2 (en) 2008-12-01 2014-04-22 Shin Poong Pharmaceutical Co., Ltd. Composition for preventing adhesion
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US20100233232A1 (en) * 2009-03-10 2010-09-16 Swanick Thomas M Fatty-acid based particles
US9345623B2 (en) 2011-08-09 2016-05-24 Biomet Biologics, Llc Surgical mesh spray and delivery system
US8776716B2 (en) 2011-08-09 2014-07-15 Biomet Biologics, Llc Surgical mesh spray and delivery system
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9220807B2 (en) * 2012-11-04 2015-12-29 Miba Medical Inc. Non-toxic cross-linker for hyaluronic acid

Also Published As

Publication number Publication date Type
WO2002036054A1 (en) 2002-05-10 application
EP1385458A1 (en) 2004-02-04 application
EP1385458A4 (en) 2008-04-09 application
JP2004529667A (en) 2004-09-30 application
US6534693B2 (en) 2003-03-18 grant
US20050281860A1 (en) 2005-12-22 application
US20020055701A1 (en) 2002-05-09 application
CA2428082A1 (en) 2002-05-10 application

Similar Documents

Publication Publication Date Title
US7087661B1 (en) Safe and effective biofilm inhibitory compounds and health-related uses thereof
US6762336B1 (en) Hemostatic sandwich bandage
Ernst et al. Immediate sealing of arterial puncture sites after cardiac catheterization and coronary angioplasty using a biodegradable collagen plug: results of an international registry
US5707647A (en) Adjunctive polymer system for use with medical device
US20050271694A1 (en) Novel modification of medical prostheses
US20030229376A1 (en) Coated surfaces for immobilizing negatively charged anticoagulating agents from blood fluid
US20070198040A1 (en) Temporarily Stiffened Mesh Prostheses
US6482223B1 (en) Clotting cascade initiating apparatus and methods of use
US20050178396A1 (en) Polymer compositions and methods for their use
US20040018228A1 (en) Compositions and methods for reducing scar tissue formation
US7972616B2 (en) Medical device applications of nanostructured surfaces
US6726923B2 (en) Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts
US20070282247A1 (en) Medical Device Applications of Nanostructured Surfaces
Singer et al. Treatment of fistulas-in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/or surgical closure of the internal fistula opening
US20050240137A1 (en) Hemostatic agent for topical and internal use
US20090043380A1 (en) Coatings for promoting endothelization of medical devices
US20070190103A1 (en) Implantable medical device with surface-eroding polyester drug delivery coating
US6224579B1 (en) Triclosan and silver compound containing medical devices
US20060135946A1 (en) Hemostasis cuff for catheter securement
US5120322A (en) Method and apparatus for treatment of fibrotic lesions
US20060045901A1 (en) Stents with drug eluting coatings
US20040052831A1 (en) Antimicrobial medical devices
Bascom Gelatin sealing to prevent blood loss from knitted arterial grafts
US20050123588A1 (en) Deployable multifunctional hemostatic agent
Brochhausen et al. Current strategies and future perspectives for intraperitoneal adhesion prevention

Legal Events

Date Code Title Description
AS Assignment

Owner name: AFMEDICA, INC., MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FISCHELL, ROBERT E.;FISHCELL, DAVID R.;FISCHELL, TIM A.;AND OTHERS;REEL/FRAME:014126/0950

Effective date: 20030511

AS Assignment

Owner name: CREDIT SUISSE, AS COLLATERAL AGENT, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:AFMEDICA, INC.;REEL/FRAME:017448/0676

Effective date: 20060323

AS Assignment

Owner name: AFMEDICA, INC., WASHINGTON

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE;REEL/FRAME:018606/0626

Effective date: 20061211